Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation

Ichidai Tanaka; Masahiro Morise; Ayako Miyazawa; Yuta Kodama; Yutaro Tamiya; Soei Gen; Akira Matsui; Tetsunari Hase; Naozumi Hashimoto; Mitsuo Sato; Yoshinori Hasegawa

doi:10.1016/j.cllc.2020.01.011

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation

Ichidai Tanaka, Masahiro Morise, Ayako Miyazawa, Yuta Kodama, Yutaro Tamiya, Soei Gen, Akira Matsui, Tetsunari Hase, Naozumi Hashimoto, Mitsuo Sato, Yoshinori Hasegawa

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

22 被引用数 (Scopus)

抄録

To investigate the clinical benefits of bevacizumab plus cytotoxic chemotherapy in lung cancer patients with EGFR mutation, we retrospectively assessed clinical data of 159 subjects. The use of the standard chemotherapy with bevacizumab provided better clinical benefit to patients with EGFR mutation than wild-type carriers.

本文言語	英語
ページ（範囲）	273-280.e4
ジャーナル	Clinical Lung Cancer
巻	21
号	3
DOI	https://doi.org/10.1016/j.cllc.2020.01.011
出版ステータス	出版済み - 05-2020
外部発表	はい

All Science Journal Classification (ASJC) codes

腫瘍学
呼吸器内科
癌研究

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1016/j.cllc.2020.01.011

他のファイルとリンク

フィンガープリント

「Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Tanaka, I., Morise, M., Miyazawa, A., Kodama, Y., Tamiya, Y., Gen, S., Matsui, A., Hase, T., Hashimoto, N., Sato, M., & Hasegawa, Y. (2020). Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation. Clinical Lung Cancer, 21(3), 273-280.e4. https://doi.org/10.1016/j.cllc.2020.01.011

@article{72032d8752384782933e0dff61bf90b5,

title = "Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation",

abstract = "To investigate the clinical benefits of bevacizumab plus cytotoxic chemotherapy in lung cancer patients with EGFR mutation, we retrospectively assessed clinical data of 159 subjects. The use of the standard chemotherapy with bevacizumab provided better clinical benefit to patients with EGFR mutation than wild-type carriers.",

author = "Ichidai Tanaka and Masahiro Morise and Ayako Miyazawa and Yuta Kodama and Yutaro Tamiya and Soei Gen and Akira Matsui and Tetsunari Hase and Naozumi Hashimoto and Mitsuo Sato and Yoshinori Hasegawa",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = may,

doi = "10.1016/j.cllc.2020.01.011",

language = "English",

volume = "21",

pages = "273--280.e4",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier Inc.",

number = "3",

}

Tanaka, I, Morise, M, Miyazawa, A, Kodama, Y, Tamiya, Y, Gen, S, Matsui, A, Hase, T, Hashimoto, N, Sato, M & Hasegawa, Y 2020, 'Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation', Clinical Lung Cancer, vol. 21, no. 3, pp. 273-280.e4. https://doi.org/10.1016/j.cllc.2020.01.011

TY - JOUR

T1 - Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation

AU - Tanaka, Ichidai

AU - Morise, Masahiro

AU - Miyazawa, Ayako

AU - Kodama, Yuta

AU - Tamiya, Yutaro

AU - Gen, Soei

AU - Matsui, Akira

AU - Hase, Tetsunari

AU - Hashimoto, Naozumi

AU - Sato, Mitsuo

AU - Hasegawa, Yoshinori

PY - 2020/5

Y1 - 2020/5

N2 - To investigate the clinical benefits of bevacizumab plus cytotoxic chemotherapy in lung cancer patients with EGFR mutation, we retrospectively assessed clinical data of 159 subjects. The use of the standard chemotherapy with bevacizumab provided better clinical benefit to patients with EGFR mutation than wild-type carriers.

AB - To investigate the clinical benefits of bevacizumab plus cytotoxic chemotherapy in lung cancer patients with EGFR mutation, we retrospectively assessed clinical data of 159 subjects. The use of the standard chemotherapy with bevacizumab provided better clinical benefit to patients with EGFR mutation than wild-type carriers.

UR - http://www.scopus.com/inward/record.url?scp=85079864583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079864583&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2020.01.011

DO - 10.1016/j.cllc.2020.01.011

M3 - Article

C2 - 32088115

AN - SCOPUS:85079864583

SN - 1525-7304

VL - 21

SP - 273-280.e4

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 3

ER -